UBS Group Boosts BioNTech (NASDAQ:BNTX) Price Target to $131.00

BioNTech (NASDAQ:BNTX) had its target price lifted by equities researchers at UBS Group from $97.00 to $131.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group’s price objective indicates a potential upside of 5.04% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on BNTX. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and lifted their price target for the company from $96.00 to $150.00 in a research note on Tuesday. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and lifted their price target for the company from $91.00 to $125.00 in a research note on Monday. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. TD Cowen lowered their target price on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Finally, Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research note on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $120.31.

BioNTech Stock Up 1.0 %

Shares of BNTX stock opened at $124.71 on Wednesday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The firm has a market capitalization of $29.65 billion, a PE ratio of 249.42 and a beta of 0.23. The stock’s 50-day simple moving average is $88.13 and its 200-day simple moving average is $89.90.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the company earned ($0.86) EPS. The firm’s quarterly revenue was down 23.3% compared to the same quarter last year. Equities analysts expect that BioNTech will post -2.8 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC purchased a new position in shares of BioNTech during the 2nd quarter worth $223,000. Granite Bay Wealth Management LLC purchased a new position in shares of BioNTech during the 2nd quarter worth $1,483,000. Scientech Research LLC purchased a new stake in BioNTech in the 2nd quarter valued at about $1,127,000. Deerfield Management Company L.P. Series C raised its holdings in BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after buying an additional 24,426 shares during the period. Finally, Employees Retirement System of Texas raised its holdings in BioNTech by 15.7% in the 2nd quarter. Employees Retirement System of Texas now owns 30,388 shares of the company’s stock valued at $2,442,000 after buying an additional 4,115 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.